Related Experiment Videos
Direct action by doxycycline against canine osteosarcoma cell proliferation and collagenase (MMP-1) activity in vitro
1Department of Comparative Medicine, College of Veterinary Medicine, University of Tennessee, Knoxville 37901-1071, USA.
Background:
Matrix metalloproteinases (MMPs) produced by tumor cells disrupt the integrity of the extracellular matrix (ECM). Inhibiting MMPs activity could significantly reduce tumor invasion and metastasis.
Materials And Methods:
Canine osteosarcoma (OSA) cells were exposed to doxycycline in vitro to determine whether this chemically modified tetracycline had antiproliferative and anticollagenolytic activity.
Results:
Doxycycline significantly reduced cell proliferation in a dose dependent manner. Doxycycline at the doses of 5 and 10 micrograms/ml suppressed cell number 50% and 72%, respectively. Furthermore, doxycycline significantly reduced collagenase activity at the doses of 10 and 20 micrograms/ml by 35% and 50%, respectively. OSA cells did not produce any endogenous collagenase in the culture medium.
Conclusions:
This study has shown that doxycycline at doses greater than 5 micrograms/ml in vitro significantly decreases cell proliferation and collagenase (MMP-1) activity. Prospective studies should be conducted to determine if doxycycline, a chemically modified tetracycline with low systemic toxicity, has specific anti-collagenase activity in vivo. Our studies indicate that canine osteosarcoma represents a suitable model for additional in vitro and in vivo studies.
Insights
Doxycycline effectively reduced canine osteosarcoma cell proliferation and collagenase activity in vitro. This chemically modified tetracycline shows promise for inhibiting tumor invasion and metastasis.
Area of Science:
- Oncology
- Biochemistry
- Pharmacology
Background:
- Tumor cells produce matrix metalloproteinases (MMPs) that degrade the extracellular matrix (ECM).
- Inhibiting MMPs is a potential strategy to reduce cancer invasion and metastasis.
Purpose of the Study:
- To investigate the antiproliferative and anticollagenolytic effects of doxycycline on canine osteosarcoma (OSA) cells in vitro.
- To assess doxycycline's potential as a therapeutic agent against OSA.
Main Methods:
- Canine osteosarcoma cells were treated with varying concentrations of doxycycline in vitro.
- Cell proliferation was measured to assess antiproliferative activity.
- Collagenase activity was measured to determine anticollagenolytic effects.
Main Results:
- Doxycycline significantly reduced OSA cell proliferation in a dose-dependent manner (50% at 5 µg/ml, 72% at 10 µg/ml).
- Doxycycline significantly inhibited collagenase activity (35% at 10 µg/ml, 50% at 20 µg/ml).
- OSA cells did not produce endogenous collagenase in culture.
Conclusions:
- Doxycycline, at doses above 5 µg/ml, significantly inhibits proliferation and collagenase (MMP-1) activity in canine osteosarcoma cells.
- Further in vivo studies are warranted to evaluate doxycycline's anti-collagenase efficacy and low systemic toxicity.
- Canine osteosarcoma serves as a relevant model for investigating doxycycline's therapeutic potential.